These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
510 related articles for article (PubMed ID: 29496986)
1. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986 [TBL] [Abstract][Full Text] [Related]
2. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab. Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793 [TBL] [Abstract][Full Text] [Related]
5. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305 [TBL] [Abstract][Full Text] [Related]
6. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844 [TBL] [Abstract][Full Text] [Related]
8. First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs). Merkul E; Sijbrandi NJ; Muns JA; Aydin I; Adamzek K; Houthoff HJ; Nijmeijer B; Van Dongen GAMS Expert Opin Drug Deliv; 2019 Aug; 16(8):783-793. PubMed ID: 31327255 [No Abstract] [Full Text] [Related]
9. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258 [TBL] [Abstract][Full Text] [Related]
10. A Systematic Evaluation of Antibody Modification and Sharma SK; Glaser JM; Edwards KJ; Khozeimeh Sarbisheh E; Salih AK; Lewis JS; Price EW Bioconjug Chem; 2021 Jul; 32(7):1177-1191. PubMed ID: 32197571 [TBL] [Abstract][Full Text] [Related]
11. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Al-Saden N; Lam K; Chan C; Reilly RM Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952 [TBL] [Abstract][Full Text] [Related]
12. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B. Ma MT; Meszaros LK; Paterson BM; Berry DJ; Cooper MS; Ma Y; Hider RC; Blower PJ Dalton Trans; 2015 Mar; 44(11):4884-900. PubMed ID: 25351250 [TBL] [Abstract][Full Text] [Related]
13. Total-Body PET and Highly Stable Chelators Together Enable Meaningful Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219 [TBL] [Abstract][Full Text] [Related]
17. Dias GM; Ramogida CF; Rousseau J; Zacchia NA; Hoehr C; Schaffer P; Lin KS; Bénard F Nucl Med Biol; 2018 Mar; 58():1-7. PubMed ID: 29291493 [TBL] [Abstract][Full Text] [Related]
18. An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt Merkul E; Muns JA; Sijbrandi NJ; Houthoff HJ; Nijmeijer B; van Rheenen G; Reedijk J; van Dongen GAMS Angew Chem Int Ed Engl; 2021 Feb; 60(6):3008-3015. PubMed ID: 33185916 [TBL] [Abstract][Full Text] [Related]
19. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600 [TBL] [Abstract][Full Text] [Related]